These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 3044800)

  • 1. Induction and maintenance therapy in multiple myeloma: a multicenter trial of MP versus VCMP.
    Peest D; Deicher H; Coldewey R; Schmoll HJ; Schedel I
    Eur J Cancer Clin Oncol; 1988 Jun; 24(6):1061-7. PubMed ID: 3044800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Induction and maintenance therapy in multiple myeloma. Results of a multicenter study].
    Peest D; Deicher H
    Onkologie; 1988 Feb; 11(1):39-43. PubMed ID: 3283624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current results of a multicenter trial in multiple myeloma.
    Peest D; Schmoll HJ; Schedel I; Deicher H; Boll J; Essers U; Gamm H; Glück S; Görg K; Gramatzki M
    Onkologie; 1986 Jun; 9(3):168-9. PubMed ID: 3528964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients.
    Bladé J; San Miguel JF; Fontanillas M; Esteve J; Maldonado J; Alcalá A; Brunet S; García-Conde J; Besalduch J; Moro MJ; Fernández-Calvo J; Conde E; Font L; Gardella S; Carnero M; Carbonell F; Martí JM; Hernández-Martín J; Ortega F; Besses C; Ribera JM; Trujillo J; Escudero ML; Rozman C; Estapé J; Montserrat E
    Hematol J; 2001; 2(4):272-8. PubMed ID: 11920260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients.
    Bladé J; San Miguel JF; Alcalá A; Maldonado J; Sanz MA; García-Conde J; Moro MJ; Alonso C; Besalduch J; Zubizarreta A
    J Clin Oncol; 1993 Jun; 11(6):1165-71. PubMed ID: 8501503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized multicentric study comparing alternating combination chemotherapy (VCMP/VBAP) and melphalan-prednisone in multiple myeloma.
    Bladé J; San Miguel J; Alcalá A; Maldonado J; García-Conde J; Moro MJ; Sanz Sanz MA; Alonso C; Zubizarreta A; Besses C
    Blut; 1990 Jun; 60(6):319-22. PubMed ID: 2198075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
    Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
    Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial treatment in multiple myeloma: no advantage of multidrug chemotherapy over melphalan-prednisone. The Myeloma Group of Western Sweden.
    Hjorth M; Hellquist L; Holmberg E; Magnusson B; Rödjer S; Westin J
    Br J Haematol; 1990 Feb; 74(2):185-91. PubMed ID: 2180471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of multiple myeloma using vincristine, cyclophosphamide, melphalan and prednisone (VCMP). Long-term results in 63 patients].
    Bladé J; Urbano A; López Guillermo A; Rozman M; Rovira M; Montserrat E; Rozman C
    Sangre (Barc); 1990 Apr; 35(2):93-7. PubMed ID: 2363100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized trial of melphalan and prednisone versus melphalan, prednisone, cyclophosphamide, MeCCNU, and vincristine in untreated multiple myeloma.
    Pavlovsky S; Saslavsky J; Tezanos Pinto M; Palmer L; Curuchet M; Lein JM; Garay G; Dragosky M; Quiroga-Micheo E; Huberman AB
    J Clin Oncol; 1984 Jul; 2(7):836-40. PubMed ID: 6376722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple myeloma in central Norway 1981-1982: a randomized clinical trial of 5-drug combination therapy versus standard therapy.
    Kildahl-Andersen O; Bjark P; Bondevik A; Bull O; Dehli O; Kvambe V; Nordahl E; Ytrehus K; Lamvik J
    Scand J Haematol; 1986 Sep; 37(3):243-8. PubMed ID: 3538367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternating combination chemotherapy (VMCP/VBAP) is not superior to melphalan/prednisone in the treatment of multiple myeloma patients stage III--a randomized study from MGCS.
    Osterborg A; Ahre A; Björkholm M; Björeman M; Brenning G; Gahrton G; Gyllenhammar H; Johansson B; Juliusson G; Järnmark M
    Eur J Haematol; 1989 Jul; 43(1):54-62. PubMed ID: 2670605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAMDex) therapy for multiple myeloma. Early results of a multicenter trial. The German Myeloma Treatment Group.
    Peest D; Deicher H; Coldewey R; von Broen IM; Cammerer U; Hein R; Hoffmann L; Konyar H; Kreuser ED; Selbach J
    Onkologie; 1990 Feb; 13(1):43-4. PubMed ID: 2186324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group Study.
    Durie BG; Dixon DO; Carter S; Stephens R; Rivkin S; Bonnet J; Salmon SE; Dabich L; Files JC; Costanzi JJ
    J Clin Oncol; 1986 Aug; 4(8):1227-37. PubMed ID: 3525768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction treatment with alpha-interferon in multiple myeloma: an interim report from MGCS.
    Mellstedt H; Osterborg A; Björkholm M; Björeman M; Brenning G; Gahrton G; Grimfors G; Gyllenhammar H; Hast R; Johansson B
    Eur J Haematol Suppl; 1989; 51():124-8. PubMed ID: 2697585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase III study of intermittent 5-drug regimen (VBCMP) versus intermittent 3-drug regimen (VMP) versus intermittent melphalan and prednisone (MP) in myelomatosis.
    Hansen OP; Clausen NA; Drivsholm A; Laursen B
    Scand J Haematol; 1985 Nov; 35(5):518-24. PubMed ID: 3911373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of multiple myeloma: a randomized study of three different regimens.
    Tribalto M; Amadori S; Cantonetti M; Franchi A; Papa G; Pileri A; Boccadoro M; Dammacco F; Vacca A; Centurioni R
    Leuk Res; 1985; 9(8):1043-9. PubMed ID: 3900591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/ autotransplantation and who were conventionally treated.
    Bladé J; San Miguel JF; Fontanillas M; Alcalá A; Maldonado J; García-Conde J; Conde E; Conzález-Brito G; Moro MJ; Escudero ML; Trujillo J; Pascual A; Rozman C; Estapé J; Montserrat E
    J Clin Oncol; 1996 Jul; 14(7):2167-73. PubMed ID: 8683251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase III study of intermittent carmustine (BCNU), cyclophosphamide, and prednisone versus intermittent melphalan and prednisone in myeloma.
    Abramson N; Lurie P; Mietlowski WL; Schilling A; Bennett JM; Horton J
    Cancer Treat Rep; 1982 Jun; 66(6):1273-7. PubMed ID: 7044535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural interferon-alpha in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden.
    Osterborg A; Björkholm M; Björeman M; Brenning G; Carlson K; Celsing F; Gahrton G; Grimfors G; Gyllenhammar H; Hast R
    Blood; 1993 Mar; 81(6):1428-34. PubMed ID: 8453092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.